Beyond the birth dose: China's strategic push to curb Hepatitis B

On World Hepatitis Day 2026, China is expanding its viral hepatitis control strategy beyond high infant immunization rates to address adult screening gaps and life-cycle protection. Crucial to this progress is a rapid surge in domestic pharmaceutical innovation, highlighted by the approval of world-first therapies like an anti-hepatitis D antibody drug and a booming biotech export sector. Together with community-level healthcare reforms, these breakthroughs support both national control efforts and global progress toward the WHO's 2030 hepatitis elimination targets.